Auscultation

OPPO Unveils New OPPO Air Glass 3 at MWC 2024, Showcasing Innovative Initiates in the Era of AI

Retrieved on: 
Tuesday, February 27, 2024
Motion, MWC, OPPO, HVS, First officer (aviation), Photography, MediaTek, EVS, Qualcomm, RBG, Atmosphere of Earth, Series, LLM, Human, System, Smartphone, Ecosystem, White paper, Auscultation, Heart, Kindness, Microsoft, Mobile phone

OPPO has established the OPPO AI Center and released the OPPO AI Smartphone White Paper as it continues to explore the forefront of AI development and implementation.

Key Points: 
  • OPPO has established the OPPO AI Center and released the OPPO AI Smartphone White Paper as it continues to explore the forefront of AI development and implementation.
  • OPPO devices, including the OPPO Find X7 Ultra, and innovative features, including the new AI Eraser, are also being showcased at MWC 2024.
  • OPPO Air Glass 3 can access OPPO's AndesGPT model via a smartphone, providing a new burdenless AI experience.
  • Ahead of the event, OPPO also announced the establishment of the OPPO AI Center and released the OPPO AI Smartphone White Paper , marking a new era in which Smartphones transition to AI Smartphones.

Alio Announces Expansion of Operations in GCC Market to the UAE Through Partnership with GulfDrug

Retrieved on: 
Monday, January 8, 2024
Kingdom, Auscultation, Partnership, KSA, FDA, Kidney disease, ESKD, Patient, Calibration, Hematocrit, Gulf Cooperation Council, GCC, Medical device

BROOMFIELD, Colo., Jan. 8, 2024 /PRNewswire/ -- Today, Alio, Inc. announces its strategic partnership with GulfDrug, one of the top medical suppliers in the United Arab Emirates (UAE). Announcement of this partnership further expands Alio's presence in the Gulf Cooperation Council (GCC), which includes the Kingdom of Saudi Arabia (KSA) and now the UAE. GulfDrug works with best-in-class global companies, like Alio, to distribute a variety of products including pharmaceuticals, surgical tools, and medical equipment. GulfDrug serves a majority of the country's End-Stage Kidney Disease (ESKD) population and intends to distribute the Alio SmartPatch to their 2,200 ESKD patients.

Key Points: 
  • announces its strategic partnership with GulfDrug , one of the top medical suppliers in the United Arab Emirates (UAE).
  • Announcement of this partnership further expands Alio's presence in the Gulf Cooperation Council (GCC), which includes the Kingdom of Saudi Arabia (KSA) and now the UAE.
  • GulfDrug works with best-in-class global companies, like Alio, to distribute a variety of products including pharmaceuticals, surgical tools, and medical equipment.
  • GulfDrug serves a majority of the country's End-Stage Kidney Disease (ESKD) population and intends to distribute the Alio SmartPatch to their 2,200 ESKD patients.

Alio Officially Enters GCC Market Through Partnership with Al Redwan

Retrieved on: 
Tuesday, December 5, 2023
Calibration, Vascular occlusion, Chronic kidney disease, ESKD, Potassium, Kidney disease, Patient, Dialysis, Kidney, FDA, Hematocrit, Auscultation, Blood, Partnership, Death, Hospital, Quality of life, Health, Alió, Kingdom

BROOMFIELD, Colo., Dec. 5, 2023 /PRNewswire/ -- Today, Alio, Inc. announces its strategic partnership with Al Redwan Medical Services Company, a leader in dialysis and medical lab trading and medical services in the Gulf region. Alio, already commercially available in the United States, has expanded its global presence to the Kingdom of Saudi Arabia to reach a greater number of kidney patients in need.

Key Points: 
  • The Alio Platform dramatically improves the technology solutions available to clinicians by delivering actionable, clinical-grade metrics and notifications at key intervention points.
  • Alio's partnership with Al Redwan allows Alio to manage the more than 3,000 End-Stage Kidney Disease (ESKD) patients for whom Al Redwan directly provides dialysis.
  • Beyond the patients already under Al Redwan's care, the partnership will also enable and facilitate the distribution of Alio products to other hospitals, providers, and partners in the region, including Diaverum.
  • Unfortunately, the technology available to date has only catered to one or two of their conditions," said Mr. Yousef Al Redwan, CEO of Al Redwan Medical Services.

Breakthrough Clinical Data: Eko Health's AI Significantly Improves Heart Disease Detection in Primary Care

Retrieved on: 
Monday, November 13, 2023
Principal, Stethoscope, Eko, VHD, Physician, Disease, Mass, Learning, Patient, Heart, FDA, Heart failure, Stroke, Auscultation, Death, Valvular heart disease, Health, American Heart Association, Medical device, AI

EMERYVILLE, Calif., Nov. 13, 2023 /PRNewswire/ -- Eko Health, Inc. (Eko), a leader in AI technology for heart and lung disease detection, today unveiled new clinical data at the 2023 American Heart Association Scientific Sessions. This data demonstrated the real-world clinical efficacy of Eko's AI-enabled SENSORA™ Platform to quickly and accurately detect structural murmurs associated with valvular heart disease. Valvular heart disease (VHD) is a medical condition present in over 50% of adults over the age of 65. VHD can lead to heart failure, stroke, and death, and if left undetected and untreated, can progress from moderate to severe within one year. Unfortunately, symptoms of VHD are frequently nonspecific, and more than half of patients with moderate to severe disease are asymptomatic, making VHD challenging to detect with conventional medical practice.

Key Points: 
  • EMERYVILLE, Calif., Nov. 13, 2023 /PRNewswire/ -- Eko Health, Inc. (Eko), a leader in AI technology for heart and lung disease detection, today unveiled new clinical data at the 2023 American Heart Association Scientific Sessions.
  • This data demonstrated the real-world clinical efficacy of Eko's AI-enabled S ENSORA™ Platform to quickly and accurately detect structural murmurs associated with valvular heart disease.
  • Valvular heart disease (VHD) is a medical condition present in over 50% of adults over the age of 65.
  • These results suggest that using Eko's AI-enabled technology in primary care may significantly increase earlier VHD discovery, facilitate appropriate patient care, and improve outcomes.

Alio's Remote Monitoring Platform Now Notifies Clinicians of Atypical Acoustic Data from Patients with Vascular Access

Retrieved on: 
Thursday, September 28, 2023
Auscultation, Infection, Partnership, Hospital, Stenosis, Hematocrit, The Rev, Research, Elective surgery, Lifeline, Dialysis, Sepsis, Friction, Patent, Patient, Risk, Medicine, Heart rate, ESKD, Health, FDA, Skin temperature, Potassium, Death, Fistula, Medical device, Medical imaging, Alió, Duplex

BROOMFIELD, Colo., Sept. 28, 2023 /PRNewswire/ -- Today, Alio, Inc. announces the release of a new feature for its remote monitoring platform which notifies clinical care teams when there is a gap in typical acoustic data from a patient's vascular access site. While the platform was FDA-cleared in March of this year to function as a stethoscope and collect auscultation data, this new notification draws the clinician's attention to a specific set of recordings which indicate the absence of typical sound data. The standard approach to monitoring a patient's vascular access has required in-person manual readings with a stethoscope. Rather than manually taking readings, the Alio SmartPatch automatically takes readings and makes it possible for clinicians to monitor a patient's vascular access remotely with no action required from the patient. 

Key Points: 
  • BROOMFIELD, Colo., Sept. 28, 2023 /PRNewswire/ -- Today, Alio, Inc. announces the release of a new feature for its remote monitoring platform which notifies clinical care teams when there is a gap in typical acoustic data from a patient's vascular access site.
  • The standard approach to monitoring a patient's vascular access has required in-person manual readings with a stethoscope.
  • Sound data from the vascular access is essential in managing an ESKD patient's condition and preserving a critical lifeline.
  • The Alio Remote Monitoring Platform makes it possible for clinicians to receive timely notifications regarding their patients.

Alio Secures Commercial Customer, Premier Dialysis, Further Extending its Reach Within the Kidney Disease Landscape

Retrieved on: 
Thursday, September 14, 2023
Auscultation, Hospital, Peritoneal dialysis, Hematocrit, Quality of life, Dialysis, Organization, Patient, Portal, Health, FDA, Skin temperature, Potassium, Kidney disease, Medical device, Nursing, Alió

BROOMFIELD, Colo., Sept. 14, 2023 /PRNewswire/ -- Today, Alio, Inc. announces official launch with commercial customer, Premier Dialysis. The two organizations are mutually aligned on helping dialysis patients improve their quality of life through better management of their condition and by empowering them with the tools necessary to do so. Both organizations also believe dialysis patients have been forced to live with the status quo for far too long and lacked access to new innovative approaches to managing their condition.

Key Points: 
  • Premier Dialysis is a dialysis solution company focused on improving quality of life through their QPLD protocol which is a dextrose-free, cycler-free dialysis methodology.
  • Premier Dialysis' trademarked approach helps patients avoid more aggressive forms of dialysis treatment and helps maintain residual kidney function which slows the progression of kidney disease.
  • While Premier Dialysis primarily serves patients receiving peritoneal dialysis, they do also serve a growing number of hemodialysis patients.
  • "Josh and the team at Premier are very much aligned with our vision of the future of kidney disease management," said David Kuraguntla, CEO and co-founder of Alio.

Modi Ventures Launches with $32 Million Tech+Bio Fund Targeting Next Frontier of Technologies Disrupting Health and Medicine

Retrieved on: 
Thursday, July 13, 2023
Auscultation, Stethoscope, Partnership, Drug development, Doctor of Philosophy, Investment, Gene editing, Section 32, General partnership, Medicine, McKinsey & Company, Tim Draper, Khosla Ventures, Sound, Artificial intelligence, Venture for America, AI, Health, Robotics, Gene, Forward, Software, Cryptocurrency, Medical device, Fine chemical, F500

HOUSTON, July 13, 2023 /PRNewswire/ -- Modi Ventures, a newly launched venture partnership investing in fund managers and founders building companies shaping the future of humanity, today announced the close of its inaugural $32 million fund, Tech+Bio Fund I. The new fund will target innovative companies transforming business in Tech Bio, life science and healthcare AI.  Despite the challenging investment economy, the fund was raised in a short period of time and oversubscribed by $2 million. Andrew Yang, former presidential candidate and founder of Venture for America was named an advisor.

Key Points: 
  • Despite the challenging investment economy, the fund was raised in a short period of time and oversubscribed by $2 million.
  • Modi Ventures was founded by Sahir Ali, a researcher, scientist and technologist recognized as a thought leader in the precision medicine and AI space.
  • "Investing in next generation technologies has always been very lucrative," said Sahir Ali, General Partner with Modi Ventures.
  • Modi Ventures has created partnerships with successful funds such as Khosla Ventures, Section 32, Artis Ventures, Draper Associates and Antler Group.

Eko Health Launches CORE 500™ Digital Stethoscope with Heart Disease Detection AI, 3-Lead ECG, and Advanced Audio Capabilities

Retrieved on: 
Tuesday, June 27, 2023
Auscultation, Heart, Bradycardia, Mayo Clinic, Emergency medicine, Ventricular fibrillation, Jawaharlal Institute of Postgraduate Medical Education and Research, Cardiovascular disease, Health, Mayo Foundation for Medical Education & Research v. United States, Stethoscope, ECG, Arrhythmia, Lung, Tachycardia, Patient, Machine learning, Algorithm, Artificial intelligence, Eko, CORE, Heart rate, Research, FDA, Medical education, Medical device

EMERYVILLE, Calif., June 27, 2023 /PRNewswire/ -- Eko Health, a leading innovator in digital health technology for heart and lung disease detection, today announced the launch of its next-generation digital stethoscope, CORE 500™. The CORE 500™ Digital Stethoscope represents over 10 years of pioneering the industry of digital auscultation (listening to heart, lung, and body sounds). Engineered to enhance diagnostic accuracy and early disease detection, the CORE 500™ combines artificial intelligence (AI) software, high-fidelity audio experience, full-color display, and 3-lead electrocardiogram (ECG) to deliver an essential patient assessment tool for healthcare professionals (HCPs).  

Key Points: 
  • EMERYVILLE, Calif., June 27, 2023 /PRNewswire/ -- Eko Health , a leading innovator in digital health technology for heart and lung disease detection, today announced the launch of its next-generation digital stethoscope, CORE 500™ .
  • The CORE 500™ Digital Stethoscope represents over 10 years of pioneering the industry of digital auscultation (listening to heart, lung, and body sounds).
  • "The CORE 500™ represents a major leap forward in digital stethoscope technology.
  • To learn more about the availability of CORE 500™ for your health system, please contact Eko Health at ekohealth.com/enterprise .

Caregility to Showcase New Acute Telehealth and AI-Enhanced Solutions for Enterprise Virtual Care at HIMSS23

Retrieved on: 
Wednesday, April 12, 2023
Nursing, Health, Technology, Telemedicine, Virtual Medicine, Hospitals, Practice Management, Artificial Intelligence, Documentation, Pressure, Partner, Multimedia, HIMSS, Future, McCormick, Auscultation, Patient, Patient safety, Exhibition, Vital, Philips, AI, Structured document, Hospital virtual Valdecilla, Conference, Safety, Pharmaceutical industry, Video game, Medical imaging, Hospital, Medical device

In booth 6815 in McCormick Place’s North Hall, the company and several of its integration and provider services partners will showcase hybrid care solutions that bring virtual resources into clinical workflows across the care continuum.

Key Points: 
  • In booth 6815 in McCormick Place’s North Hall, the company and several of its integration and provider services partners will showcase hybrid care solutions that bring virtual resources into clinical workflows across the care continuum.
  • Eko Health will demonstrate its line of Virtual Auscultation solutions for remote heart function and lung sound assessment.
  • Caregility’s unparalleled partner ecosystem brings added value to virtual care programs, allowing care teams to layer in additional tools to further tailor clinical workflows.
  • Caregility’s clinically informed software applications support virtual consultations and engagement and continuous patient observation to enable hybrid care programs such as virtual nursing and virtual sitting.

Alio and Carium Announce Partnership to Increase Access to Healthcare Through Remote Patient Monitoring

Retrieved on: 
Monday, March 27, 2023
Auscultation, Partnership, Prevalence, Hematocrit, Organization, Hospital, Patient, CXP, Ecosystem, FDA, Skin temperature, Health, Potassium, Caregiver, Nursing, Pharmaceutical industry, Alió

BROOMFIELD, Colo., March 27, 2023 /PRNewswire/ -- Today, Alio, Inc. and Carium announced their partnership focused on improving health outcomes for patients with chronic conditions and increasing healthcare accessibility through Alio's remote patient monitoring platform. The two companies share a common goal of leveraging innovative technology to improve chronic care management while also improving the patient and clinician experience.

Key Points: 
  • Given their expansive ecosystem, Carium understands the importance of creating and deploying solutions that fit seamlessly into existing clinician workflows.
  • Alio is a FDA cleared, non-invasive, and multimetric remote patient monitoring platform consisting of the wearable SmartPatch™, hub, and clinician-facing portal.
  • Alio's remote patient monitoring platform will be available through commercial agreements made directly with Alio as well as through Carium's network of solutions.
  • Through this partnership we intend to make their technology more widely available so it can have an even greater impact for vulnerable patient populations."